de Jong EMGJ - Search Results

1

Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID).

Kwee KV, Murk JL, Yin Q, Visch MB, Davidson L, de Jong EMGJ, van den Reek JMPA, Tjioe M. Kwee KV, et al. Among authors: de jong emgj. J Dermatolog Treat. 2023 Dec;34(1):2161297. doi: 10.1080/09546634.2022.2161297. J Dermatolog Treat. 2023. PMID: 36545844 Free article.

2

Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.

Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM. Berends MA, et al. J Dermatolog Treat. 2007;18(2):76-83. doi: 10.1080/09546630601121086. J Dermatolog Treat. 2007. PMID: 17520463 Clinical Trial.

3

The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.

Langewouters AM, Bovenschen HJ, De jong EM, Van Erp PE, Van De Kerkhof PC. Langewouters AM, et al. J Dermatolog Treat. 2007;18(5):279-85. doi: 10.1080/09546630701395044. J Dermatolog Treat. 2007. PMID: 17852631 Clinical Trial.

4

The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.

Langewouters AM, Van Erp PE, De Jong EM, Van De Kerkhof PC. Langewouters AM, et al. J Dermatolog Treat. 2006;17(6):362-9. doi: 10.1080/09546630601028794. J Dermatolog Treat. 2006. PMID: 17853311 Clinical Trial.

5

Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.

Driessen RJ, Boezeman JB, Van De Kerkhof PC, De Jong EM. Driessen RJ, et al. J Dermatolog Treat. 2009;20(1):42-7. doi: 10.1080/09546630802225702. J Dermatolog Treat. 2009. PMID: 18649164

6

Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.

Kop EN, Körver JE, Van Ruysevelt D, De Jong EM, Van der Valk PG, Van de Kerkhof PC. Kop EN, et al. J Dermatolog Treat. 2009;20(1):67-9. doi: 10.1080/09546630802206694. J Dermatolog Treat. 2009. PMID: 18651300

7

Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals.

De Jager ME, Van de Kerkhof PC, De Jong EM, Seyger MM. De Jager ME, et al. J Dermatolog Treat. 2009;20(5):254-8. doi: 10.1080/09546630902911847. J Dermatolog Treat. 2009. PMID: 19418330

8

Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice.

van den Reek JM, van Lümig PP, Kievit W, Zweegers J, van de Kerkhof PC, Seyger MM, de Jong EM. van den Reek JM, et al. J Dermatolog Treat. 2013 Oct;24(5):361-8. doi: 10.3109/09546634.2012.751483. Epub 2013 May 6. J Dermatolog Treat. 2013. PMID: 23194389

9

Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases.

van den Reek JM, van Lümig PP, Janssen M, Schers HJ, Hendriks JC, van de Kerkhof PC, Seyger MM, de Jong EM. van den Reek JM, et al. J Eur Acad Dermatol Venereol. 2014 Jan;28(1):27-33. doi: 10.1111/jdv.12041. Epub 2012 Dec 6. J Eur Acad Dermatol Venereol. 2014. PMID: 23216663

10

Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.

van den Reek JM, van Lümig PP, Driessen RJ, van de Kerkhof PC, Seyger MM, Kievit W, de Jong EM. van den Reek JM, et al. Br J Dermatol. 2014 Feb;170(2):415-24. doi: 10.1111/bjd.12648. Br J Dermatol. 2014. PMID: 24117023

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

289 results

Search Page